Aclaris Therapeutics Inc
Exchange: IEX Type: Common StockNot available right now.
Remote Buying of Aclaris Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Aclaris Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Xilio Therapeutics Seeks $125 Million In U.S. IPO via Seeking Alpha
Esperion Therapeutics to reduce workforce by 40% via Yahoo Finance
: Turning Point Therapeutics stock price target cut to $53 from $75 at Stifel Nicolaus via MarketWatch
Relay Therapeutics Inc (RLAY): Price Now Near $35.71; Daily Chart Shows Downtrend on 20 Day Basis via ETF Daily News
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
Analysis is available when the exchange & market are open.